Argenx Projects $4.15 Billion in Sales by 2025 and Plans Four Phase 3 Studies
Dutch biotechnology group argenx has announced preliminary net sales of $4.15 billion for fiscal year 2025, a 90% increase year-over-year. The company is currently treating approximately 19,000 patients with its drug VYVGART and expects four registration study results in 2026.
According to the press release, argenx recorded preliminary global net sales of $4.15 billion for the year 2025, marking a 90% increase from the previous fiscal year. The fourth quarter of 2025 alone generated approximately $1.29 billion in revenue. The group reports that VYVGART, its flagship treatment approved for three indications including generalized myasthenia and chronic inflammatory demyelinating polyneuropathy, is currently prescribed to about 19,000 patients worldwide. The company notes that these financial figures are preliminary, unaudited, and subject to adjustment before the full results are published in February 2026.
Upcoming Clinical Study Results
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The group expects four registration study results in 2026 for efgartigimod and empasiprubart. Argenx specifically aims to expand the indication of VYVGART to seronegative generalized myasthenia, with a planned launch by the end of 2026 pending approval. The group also anticipates publishing phase 3 data for ocular myasthenia in the first quarter of 2026 and for primary immune thrombocytopenic purpura in the fourth quarter of 2026, aiming for a launch in the United States. Regarding empasiprubart, an antibody targeting C2, the initial phase 3 results for multifocal motor neuropathy are expected in the fourth quarter of 2026.
Pipeline Development and Executive Changes
According to the press release, argenx anticipates that its pipeline will include ten molecules in clinical development by the end of 2026, four of which will be in phase 3. The group advanced four new molecules in 2025, including ARGX-213 and ARGX-124 targeting FcRn, ARGX-109 targeting IL-6, and ARGX-121 targeting IgA. Three new molecules are expected to enter phase 1 in 2026. Additionally, the company indicates that Karen Massey, currently Chief Operating Officer, will succeed Tim Van Hauwermeiren as CEO. He will take on the role of non-executive chairman of the board, pending shareholder approval at the general meeting on May 6, 2026. Sandrine Piret-Gérard has been appointed as the director of commercialization.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 4 605 millions de dollars
Quarterly revenue: 4 605 millions de dollars
Revenue growth: 57,4 %
Net income: 1 344 millions de dollars
Guidance from the release
argenx remains on track to achieve its 'Vision 2030' anchored in the ambition to treat 50,000 patients globally
Risks mentioned
The risk that early stage clinical trials may not be predictive of results in later stage or large scale clinical trials
Demand and commercialization risks for argenx's products and product candidates, including new indications
Regulatory and pricing uncertainties for argenx's products and product candidates if approved
Opportunities identified
Vision 2030 targets: treat 50,000 patients globally, secure 10 labeled indications, and progress five pipeline candidates
Multiple label and indication expansions for VYVGART being pursued across additional autoimmune diseases
Next-generation FcRn molecules (ARGX-213 Phase 3-ready, ARGX-124 in Phase 1) advancing through development
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
